Forward Looking Statement
Statements on this website, other than statements of historical facts, constitute forward looking statements regarding, among other things, the future business operations of StemCells, Inc. or its wholly-owned subsidiaries (collectively, the “Company"). Forward looking statements may include statements regarding the status and future promise of our approach to cell-based therapeutics, our CNS and liver programs and the status or timing of our current or proposed clinical trials, the status and prospects of our tools and technologies for drug testing and screening, the quality of our scientific and management teams, the strength of our IP portfolio, the value of the Company, and our near term milestones and future outlook.
The Company’s actual results may vary materially from those contemplated in these forward looking statements due to risks and uncertainties to which the Company is subject, including uncertainties regarding the Company’s ability to obtain the significant additional capital resources needed to conduct the time-consuming research, Pre-clinical development and clinical trials that are necessary for regulatory approvals and to establish production and marketing capabilities, if such approvals are obtained. Lack of necessary funds may require the Company to delay, reduce or eliminate some or all of its research and product development programs or to license its potential products or technologies to third parties.
Moreover, the Company’s stem cell technology is at the pre-clinical or early clinical stage and has not yet led to the development of any therapeutic product. There can be no assurance that any therapeutic products now under development or generated in the future by the Company will: (i) survive and persist in the desired locations, (ii) provide the therapeutic benefits intended, (iii) properly differentiate and integrate into existing tissue in the desired manner, or (iv) not cause tumors or other adverse side effects. There can be no assurance that the Company will achieve revenues from product sales or become profitable. Other risks and uncertainties are described under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2009, and in its subsequent reports on Form 10-Q and Form 8-K available here. As a result of all of these and other factors, investment in the Company is subject to a high degree of risk, including a substantial risk of loss. Investors should carefully consider these risks before making any investment in the Company. Forward-looking statements speak only as of their respective dates and we assume no responsibility to update or revise any of the forward-looking statements to reflect future events, trends or circumstances.